Johnson & Johnson has agreed to take over Intra-Cellular Therapies in a deal worth up to $14.6 billion – the second biopharma M&A announcement today. The $132-per-share agreement comes a few months ...
Prognostics and Health Management (PHM) aims at assessing and predicting the degradation of structures, systems and components (SSCs), so as to allow anticipating failures and, thus, avoiding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results